CDX2 immunostaining in primary and metastatic germ cell tumours of the testis
dc.contributor.buuauthor | Atalay, Fatma Öz | |
dc.contributor.buuauthor | Vuruşkan, Berna Aytaç | |
dc.contributor.buuauthor | Vuruşkan, Hakan | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAH-9746-2021 | tr_TR |
dc.contributor.scopusid | 15623010600 | tr_TR |
dc.contributor.scopusid | 57053559100 | tr_TR |
dc.contributor.scopusid | 6507328150 | tr_TR |
dc.date.accessioned | 2023-05-16T11:27:01Z | |
dc.date.available | 2023-05-16T11:27:01Z | |
dc.date.issued | 2016-08-01 | |
dc.description.abstract | Objective: To evaluate the immunohistochemical staining pattern of caudal type homeobox 2 (CDX2) protein in germ cell tumours (GCTs) of the testis. Methods: This study reassessed archival tissue samples collected from patients diagnosed with primary and metastatic testicular GCTs for CDX2 immunoreactivity using standard immunohistochemical techniques. Positive nuclear immunostaining was evaluated with regard to both the staining intensity and the extent of the staining. Results: Tissue sections from primary and metastatic testicular GCTs (n = 104), germ cell neoplasia in situ (GCNis) (n = 5) and benign testicles (n = 15) were analysed. The GCNis and benign testicular tissues showed no immunoreactivity for CDX2. Strong and diffuse staining of CDX2 was demonstrated only in the mature colonic epithelium of teratomas in both primary and metastatic GCTs. CDX2 positivity in other tumours (one pure yolk sac tumour, one yolk sac component of a mixed GCT and one pure seminoma) was infrequent, and was only weak and focal. Conclusions: CDX2 immunostaining should be interpreted based on both the staining intensity and the extent of staining so as not to cause misdiagnosis. Teratomas with colonic-type epithelium should be considered in the differential diagnosis if a metastatic tumour with an unknown primary shows prominent CDX2 immunostaining. | en_US |
dc.identifier.citation | Atalay, F. Ö. vd. (2016). "CDX2 immunostaining in primary and metastatic germ cell tumours of the testis". Journal of International Medical Research, 44(6), 1323-1330. | en_US |
dc.identifier.endpage | 1330 | tr_TR |
dc.identifier.issn | 0300-0605 | |
dc.identifier.issn | 1473-2300 | |
dc.identifier.issue | 6 | tr_TR |
dc.identifier.pubmed | 28322096 | tr_TR |
dc.identifier.scopus | 2-s2.0-85006427724 | tr_TR |
dc.identifier.startpage | 1323 | tr_TR |
dc.identifier.uri | https://doi.org/10.1177/0300060516665472 | |
dc.identifier.uri | https://journals.sagepub.com/doi/10.1177/0300060516665472 | |
dc.identifier.uri | http://hdl.handle.net/11452/32679 | |
dc.identifier.volume | 44 | tr_TR |
dc.identifier.wos | 000390675500017 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications | en_US |
dc.relation.journal | Journal of International Medical Research | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Research & experimental medicine | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | CDX2 | en_US |
dc.subject | Germ cell tumour | en_US |
dc.subject | Immunohistochemistry | en_US |
dc.subject | Teratoma | en_US |
dc.subject | Testis | en_US |
dc.subject | Immunohistochemical survey | en_US |
dc.subject | Intestinal metaplasia | en_US |
dc.subject | Yolk-sac | en_US |
dc.subject | Expression | en_US |
dc.subject | Adenocarcinoma | en_US |
dc.subject | Origin | en_US |
dc.subject | Marker | en_US |
dc.subject | Differentiation | en_US |
dc.subject | Carcinomas | en_US |
dc.subject | Neoplasms | en_US |
dc.subject.emtree | Transcription factor Cdx2 | en_US |
dc.subject.emtree | CDX2 protein, human | en_US |
dc.subject.emtree | Transcription factor Cdx2 | en_US |
dc.subject.emtree | Tumor marker | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer patient | en_US |
dc.subject.emtree | Cancer tissue | en_US |
dc.subject.emtree | Choriocarcinoma | en_US |
dc.subject.emtree | Colon epithelium | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Embryonal carcinoma | en_US |
dc.subject.emtree | Germ cell cancer | en_US |
dc.subject.emtree | Germ cell neoplasia in situ | en_US |
dc.subject.emtree | Germ cell tumor | en_US |
dc.subject.emtree | Histopathology | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human tissue | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Immunoreactivity | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Metastasis | en_US |
dc.subject.emtree | Primary tumor | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Seminiferous tubule | en_US |
dc.subject.emtree | Seminoma | en_US |
dc.subject.emtree | Staining | en_US |
dc.subject.emtree | Testis cancer | en_US |
dc.subject.emtree | Testis teratoma | en_US |
dc.subject.emtree | Testis tissue | en_US |
dc.subject.emtree | Testis tumor | en_US |
dc.subject.emtree | Tissue section | en_US |
dc.subject.emtree | Tumor localization | en_US |
dc.subject.emtree | Yolk sac | en_US |
dc.subject.emtree | Yolk sac tumor | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Carcinoma, embryonal | en_US |
dc.subject.emtree | Differential diagnosis | en_US |
dc.subject.emtree | Gene expression | en_US |
dc.subject.emtree | Genetics | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Neoplasms, germ cell and embryonal | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Procedures | en_US |
dc.subject.emtree | Teratoma | en_US |
dc.subject.emtree | Testicular neoplasms | en_US |
dc.subject.emtree | Testis | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Biomarkers, tumor | en_US |
dc.subject.mesh | Carcinoma, embryonal | en_US |
dc.subject.mesh | CDX2 transcription factor | en_US |
dc.subject.mesh | Diagnosis, differential | en_US |
dc.subject.mesh | Gene expression | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunohistochemistry | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Neoplasms, germ cell and embryonal | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Seminoma | en_US |
dc.subject.mesh | Staining and labeling | en_US |
dc.subject.mesh | Teratoma | en_US |
dc.subject.mesh | Testicular neoplasms | en_US |
dc.subject.mesh | Testis | en_US |
dc.subject.scopus | Transcription Factor Cdx2; Cadherin; Homeobox Genes | en_US |
dc.subject.wos | Medicine, research & experimental | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.title | CDX2 immunostaining in primary and metastatic germ cell tumours of the testis | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 | en_US |